Table 2.
Clinical factors associated with overall survival.
| Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | ||
| Age, year | <75 | Reference | |||
| ≥75 | 1.37 (0.91–2.06) | 0.137 | |||
| Sex | Female | Reference | |||
| Male | 0.93 (0.64–1.37) | 0.727 | |||
| PS | 0–1 | Reference | Reference | ||
| ≥2 | 2.95 (1.94–4.50) | <0.005 | 2.48 (1.58–3.88) | <0.005 | |
| Smoking status | Never smoker | Reference | Reference | ||
| Smoker | 0.64 (0.42–0.99) | 0.046 | 0.74 (0.48–1.15) | 0.181 | |
| Histology | Non-squamous | Reference | |||
| Squamous | 1.35 (0.90–2.01) | 0.143 | |||
| PD-L1 status | <50% | Reference | Reference | ||
| ≥50% | 0.57 (0.41–0.81) | 0.002 | 0.54 (0.38–0.78) | <0.005 | |
| Stage | IVA | Reference | Reference | ||
| IVB | 1.54 (1.11–2.14) | 0.010 | 1.16 (0.82–1.66) | 0.403 | |
| CYFRA 21-1 | ≤3.5 ng/mL | Reference | Reference | ||
| >3.5 ng/mL | 2.47 (1.77–3.43) | <0.005 | 1.99 (1.38–2.88) | <0.005 | |
| CEA | ≤5.0 ng/mL | Reference | Reference | ||
| >5.0 ng/mL | 1.72 (1.24–2.39) | <0.005 | 1.36 (0.97–1.91) | 0.072 | |
CEA, carcinoembryonic antigen; CI, confidence interval; CYFRA 21-1, cytokeratin fraction 21–1; HR, hazard ratio; PD-L1, programmed cell death ligand 1; PS, performance status.